Multiple Sclerosis Clinical Trial

Vancomycin Study in Multiple Sclerosis (MS)

Summary

The overall goal of this study is to elucidate a mechanism by which vancomycin modulates the gut-brain axis in multiple sclerosis (MS). The gut microbiome plays an important role in autoimmunity, including MS. However, the identity of gut microbes modulating neuroinflammation in MS and their mechanisms of action remain obscure. Hence, here the research team proposes to investigate the effects of vancomycin on the gut microbiota composition, peripheral immune function, and brain MRI lesions in MS patients.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

aged 18 - 50
newly diagnosed MS (2017 McDonald criteria), CIS or RIS patients, who have experienced symptoms no earlier than the past year
treatment naive
able to understand the risks, benefits, and alternatives of participation and give meaningful consent

Exclusion Criteria:

antibiotic use within the past 90 days;
pre- or probiotic use within past month or corticosteroids use within the past month;
use of tobacco products within the past 1 month;
history of treatment with immunosuppressants;
history of gastroenteritis within the past month or diagnosis with a chronic infectious disease, i.e. hepatitis B, C or HIV;
pregnancy or less than 6 months postpartum;
irritable bowel syndrome and other bowel dysfunction such as constipation;
history of bowel surgery;
inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, diabetes and any other auto-immune illness;
diagnosis with another neurological disease, behavioral or psychiatric conditions that would be incompatible with a safe and successful participation in the study (such as severe major depression, schizophrenia and presence of psychotic symptoms);
eating disorders such as anorexia nervosa, bulimia, or binge eating syndrome;
travel outside of the country within the past month;
contraindication to vancomycin including estimated glomerular filtration rate of <60ml/min, impaired hearing or known allergy.
Contraindication to MRI such as implanted metallic objects

Study is for people with:

Multiple Sclerosis

Phase:

Phase 1

Estimated Enrollment:

12

Study ID:

NCT05539729

Recruitment Status:

Recruiting

Sponsor:

Icahn School of Medicine at Mount Sinai

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai
New York New York, 10029, United States More Info
Susan E Filomena, BA
Contact
212-241-3841
[email protected]
Abigail Hintermeister, MPA
Contact
212-241-3391
[email protected]
Stephanie K Tankou
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 1

Estimated Enrollment:

12

Study ID:

NCT05539729

Recruitment Status:

Recruiting

Sponsor:


Icahn School of Medicine at Mount Sinai

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.